$2.29T
Total marketcap
$377.6B
Total volume
BTC 55.31%     ETH 9.32%
Dominance

ProPhase Labs PRPH Stock

$0.14   -1.420773%
Add to favorites
Market Cap
$640.92K
LOW - HIGH [24H]
$0.14 - $0.15
VOLUME [24H]
$18.88K
P/E Ratio
0
Earnings per share
-$2.75
ISIN
US74345W1080
Price   Prediction

ProPhase Labs Price Chart

Sorry, that's all we've gotfor now...

ProPhase Labs PRPH Financial and Trading Overview

ProPhase Labs stock price 0.14 USD
Previous Close 0.1 USD
Open 0.1 USD
Bid 0.1 USD x 1493900
Ask 0.11 USD x 704400
Day's Range 0.1 - 0.12 USD
52 Week Range 0.07 - 6.7 USD
Volume 37.03K USD
Avg. Volume 155.03K USD
Market Cap 568.44K USD
Beta (5Y Monthly) 0.168
PE Ratio (TTM) N/A
EPS (TTM) -2.75 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date May 24, 2022
1y Target Est N/A

PRPH Valuation Measures

Enterprise Value 9.56M USD
Trailing P/E N/A
Forward P/E 0.25
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.11600816
Price/Book (mrq) 0.2197802
Enterprise Value/Revenue 1.952
Enterprise Value/EBITDA -0.803

Trading Information

ProPhase Labs Stock Price History

Beta (5Y Monthly) 0.168
52-Week Change -96.84%
S&P500 52-Week Change 27.29%
52 Week High 6.7 USD
52 Week Low 0.07 USD
50-Day Moving Average 0.11 USD
200-Day Moving Average 1.62 USD

PRPH Share Statistics

Avg. Volume (3 month) 155.03K USD
Avg. Daily Volume (10-Days) 22.25K USD
Shares Outstanding 4.74M
Float 8.65M
Short Ratio 0.08
% Held by Insiders 5.05%
% Held by Institutions 0.15%
Shares Short 30.02K
Short % of Float 0.70%
Short % of Shares Outstanding 0.64%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:10

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) December 31, 2025
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -272.49%
Operating Margin (ttm) -330.24%
Gross Margin 39.57%
EBITDA Margin -243.082%

Management Effectiveness

Return on Assets (ttm) -16.64%
Return on Equity (ttm) -359.060%

Income Statement

Revenue (ttm) 4.9M USD
Revenue Per Share (ttm) 0.58 USD
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) 1.94M USD
EBITDA -11911000 USD
Net Income Avi to Common (ttm) -21996000 USD
Diluted EPS (ttm) -19.8
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 90K USD
Total Cash Per Share (mrq) 0.01 USD
Total Debt (mrq) 8.62M USD
Total Debt/Equity (mrq) 175.91 USD
Current Ratio (mrq) 0.107
Book Value Per Share (mrq) 0.546

Cash Flow Statement

Operating Cash Flow (ttm) -8344000 USD
Levered Free Cash Flow (ttm) 42.96M USD

Profile of ProPhase Labs

Country United States
State NY
City Garden City
Address 711 Stewart Avenue
ZIP 11530
Phone 215 345 0919
Website https://www.prophaselabs.com
Industry Diagnostics & Research
Sector(s) Healthcare
Full Time Employees N/A

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Q&A For ProPhase Labs Stock

What is a current PRPH stock price?

ProPhase Labs PRPH stock price today per share is 0.14 USD.

How to purchase ProPhase Labs stock?

You can buy PRPH shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for ProPhase Labs?

The stock symbol or ticker of ProPhase Labs is PRPH.

Which industry does the ProPhase Labs company belong to?

The ProPhase Labs industry is Diagnostics & Research.

How many shares does ProPhase Labs have in circulation?

The max supply of ProPhase Labs shares is 4.74M.

What is ProPhase Labs Price to Earnings Ratio (PE Ratio)?

ProPhase Labs PE Ratio is now.

What was ProPhase Labs earnings per share over the trailing 12 months (TTM)?

ProPhase Labs EPS is -2.75 USD over the trailing 12 months.

Which sector does the ProPhase Labs company belong to?

The ProPhase Labs sector is Healthcare.

ProPhase Labs PRPH included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
US Tech Composite IXIC 26853.98 USD
-0.89
8.32B USD 26769.16 USD 27130.88 USD 8.32B USD
US Tech Composite Total Return XCMP 33104.2 USD
-0.89
32999.64 USD 33445.55 USD
US Tech Capital Market Composite RCMP 148.96 USD
-1.84
148.23 USD 151.02 USD
Select currency